Viewing Study NCT03206866


Ignite Creation Date: 2025-12-24 @ 4:42 PM
Ignite Modification Date: 2026-01-10 @ 2:48 PM
Study NCT ID: NCT03206866
Status: UNKNOWN
Last Update Posted: 2017-07-02
First Post: 2017-06-29
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
Sponsor: Mansoura University
Organization:

Study Overview

Official Title: Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
Status: UNKNOWN
Status Verified Date: 2017-06
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identified from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: